NCF1 and type 2 diabetes mellitus: Regulatory network analysis suggested hsa-miR-127-5p as a potential upstream regulator of BLVRB, and methylene blue was identified as a potential targeting drug.<h4>Conclusion</h4>This study identifies novel immune-related candidate genes, particularly BLVRB and NCF1, for T2DM.